Vitality is a top 4 Provider of Private Medical Insurance in the UK. Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK. Nearly 60% of all Patients With Private Health Insurance in the Greater London Market now Have Access to Aclarion's Nociscan. BROOMFIELD, CO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algori ...

Core Insights - Aclarion, Inc. has achieved a significant milestone with the second payer coverage of its Nociscan technology by Aviva in London, UK, enhancing access for patients suffering from chronic low back pain [1][2] - Aviva, a leading private medical insurance provider in the UK, covers approximately 14% of the private medical insurance market, with an estimated 1.2 million insured customers [2] - The collaboration with The London Clinic allows Nociscan to be available to 45% of patients with private insurance in the Greater London area, following AXA's coverage [2][3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in diagnosing and treating patients [4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine, providing critical insights for treatment optimization [4] Market Context - In the UK, self-pay and private medical insurance account for nearly 70% of private hospital revenues, indicating a growing trend in private medical insurance adoption [2] - The London Clinic has integrated Nociscan as a key decision support tool for diagnosing chronic low back pain, which affects up to one third of the UK adult population annually [3]

Core Insights - Aclarion, Inc. has achieved a significant milestone with the second payer coverage of its Nociscan technology by Aviva in London, UK, enhancing access for patients suffering from chronic low back pain [1][2] - Aviva is one of the top four private medical insurers in the UK, holding approximately 14% of the private medical insurance market, which translates to around 1.2 million insured customers [2][3] - The collaboration with Aviva, alongside AXA, allows Nociscan to be accessible to approximately 45% of patients with private insurance in the Greater London area [2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in diagnosing and treating patients [4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine, providing critical insights for treatment optimization [4] Market Context - In the UK, self-pay and private medical insurance account for nearly 70% of private hospital revenues, indicating a growing trend in the adoption of private medical insurance [2] - The London Clinic has integrated Nociscan as a key decision support tool for diagnosing chronic low back pain, which affects up to one-third of the UK adult population annually [3]

Core Insights - Aclarion has secured its first payer coverage for Nociscan from AXA, marking a significant milestone for the company in the UK healthcare market [1][2] - The approval by AXA, which holds approximately 30% of the private medical insurance market in the UK, is expected to drive volume and revenue for Aclarion [1][2] - Nociscan is being adopted by The London Clinic as a decision support tool for diagnosing and treating chronic low back pain, expanding access for insured patients [3] Company Overview - Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in treatment [4] - The Nociscan platform is the first evidence-supported SaaS solution designed to differentiate between painful and non-painful discs in the lumbar spine [4] - The company aims to optimize clinical treatments by leveraging biomarkers and augmented intelligence algorithms [4] Market Context - In the UK, self-pay and private medical insurance account for nearly 70% of private hospital revenues, indicating a growing market for private medical insurance [2] - AXA is one of the four leading private medical insurers in the UK, with an estimated 3 million insured customers [2]

Core Insights - Aclarion has secured its first payer coverage for Nociscan from AXA, marking a significant milestone for the company in the UK healthcare market [1][2] - The approval by AXA, which holds approximately 30% of the private medical insurance market in the UK, is expected to drive volume and revenue for Aclarion [1][2] - Nociscan is being adopted by The London Clinic as a decision support tool for diagnosing and treating chronic low back pain, expanding access for insured patients [3] Company Overview - Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in treatment [4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [4] - The company aims to optimize clinical treatments by leveraging biomarkers and augmented intelligence algorithms [4] Market Context - In the UK, self-pay and private medical insurance account for nearly 70% of private hospital revenues, indicating a growing market for private medical insurance [2] - AXA is one of the four leading private medical insurers in the UK, with an estimated 3 million insured customers [2]

Established in 1932, the London Clinic is the UK's Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers ...

Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) Delaware 47 ...

LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system LIFEHAB is targeting enrollment to begin in the second quarter of 2024 BROOMFIELD, CO, April 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-K _________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) Delaware 47-3324725 (State or ...